📊 SGHT Key Takeaways
Is Sight Sciences, Inc. (SGHT) a Good Investment?
Sight Sciences is a pre-profitability medical device company facing a critical juncture with exceptional 86% gross margins undermined by declining revenue (-3.1% YoY), massive operating losses (-63% margin), and negative operating cash flow (-$7.0M). Without rapid revenue growth and operational efficiency improvements, the company's cash runway will be insufficient to reach profitability.
Sight Sciences, Inc. Key Strengths (SGHT)
- Exceptional gross margin of 86.2% demonstrates strong product-market fit and pricing power in surgical instruments market
- Strong cash position of $85.0M with excellent liquidity ratios (5.86x current, 5.48x quick) provides operational cushion
- Moderate leverage with 0.79x debt/equity ratio offers financial flexibility for strategic reallocation
SGHT Stock Risks: Sight Sciences, Inc. Investment Risks
- Revenue declining 3.1% YoY with stagnant $19.7M base—no growth trajectory and shrinking top line
- Operating margin of -63% and operating cash burn of -$7.0M indicate fundamentally unscalable business model despite product quality
- Negative interest coverage ratio of -9.8x and sustained cash burn create existential runway risk if revenue inflection does not materialize soon
Key Metrics to Watch
- Quarterly revenue growth rate—must reverse negative YoY trend to validate market demand
- Operating expense ratio trajectory—path to operating profitability is only viable with structural cost reductions given stalled revenue
- Monthly operating cash burn and quarters of cash runway remaining—critical for survival timeline assessment
Sight Sciences, Inc. (SGHT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.86x current ratio provides a solid financial cushion.
SGHT Profit Margin, ROE & Profitability Analysis
SGHT vs Healthcare Sector: How Sight Sciences, Inc. Compares
How Sight Sciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Sight Sciences, Inc. Stock Overvalued? SGHT Valuation Analysis 2026
Based on fundamental analysis, Sight Sciences, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Sight Sciences, Inc. Balance Sheet: SGHT Debt, Cash & Liquidity
SGHT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Sight Sciences, Inc.'s revenue has grown significantly by 63% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.03 indicates the company is currently unprofitable.
SGHT Revenue Growth, EPS Growth & YoY Performance
SGHT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $17.5M | -$13.0M | $-0.24 |
| Q3 2025 | $19.9M | -$8.2M | $-0.16 |
| Q2 2025 | $19.6M | -$11.9M | $-0.23 |
| Q1 2025 | $17.5M | -$14.2M | $-0.28 |
| Q3 2024 | $20.0M | -$11.1M | $-0.22 |
| Q2 2024 | $21.4M | -$12.3M | $-0.25 |
| Q1 2024 | $18.8M | -$16.3M | $-0.33 |
| Q3 2023 | $18.7M | -$13.0M | $-0.27 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Sight Sciences, Inc. Dividends, Buybacks & Capital Allocation
SGHT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Sight Sciences, Inc. (CIK: 0001531177)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SGHT
What is the AI rating for SGHT?
Sight Sciences, Inc. (SGHT) has an AI grade of C with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SGHT's key strengths?
Claude: Exceptional gross margin of 86.2% demonstrates strong product-market fit and pricing power in surgical instruments market. Strong cash position of $85.0M with excellent liquidity ratios (5.86x current, 5.48x quick) provides operational cushion.
What are the risks of investing in SGHT?
Claude: Revenue declining 3.1% YoY with stagnant $19.7M base—no growth trajectory and shrinking top line. Operating margin of -63% and operating cash burn of -$7.0M indicate fundamentally unscalable business model despite product quality.
What is SGHT's revenue and growth?
Sight Sciences, Inc. reported revenue of $19.7M.
Does SGHT pay dividends?
Sight Sciences, Inc. does not currently pay dividends.
Where can I find SGHT SEC filings?
Official SEC filings for Sight Sciences, Inc. (CIK: 0001531177) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SGHT's EPS?
Sight Sciences, Inc. has a diluted EPS of $-0.24.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is SGHT's fundamental grade?
Based on our AI fundamental analysis in May 2026, Sight Sciences, Inc. has a C grade with 78% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is SGHT stock overvalued or undervalued?
Valuation metrics for SGHT: ROE of -24.1% (sector avg: 15%), net margin of -65.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is SGHT's AI grade for 2026?
Our dual AI analysis gives Sight Sciences, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SGHT's free cash flow?
Sight Sciences, Inc.'s operating cash flow is $-7.0M, with capital expenditures of $60.0K. FCF margin is -36.0%.
How does SGHT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -65.9% (avg: 12%), ROE -24.1% (avg: 15%), current ratio 5.86 (avg: 2).